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Summary. The purpose of this work was to develop a
definition of myelofibrosis with myeloid metaplasia (MMM)
using diagnostic criteria that would remain valid within the
set of patients with chronic myeloproliferative disorders or
myelodysplastic syndromes. A list of 12 names for the disease
and 37 diagnostic criteria were proposed to a Consensus
Panel of 12 Italian experts who ranked them in order so as to
identify a core set of criteria. The Panel was then asked to
score the diagnosis of 46 patient profiles as appropriate or
not appropriate for MMM. Using the experts’ consensus as
the gold standard, the performance of 90 possible definitions
of the disease obtained through the core set was evaluated.
‘Myelofibrosis with myeloid metaplasia’ ranked as the
preferred name of the disease. Necessary criteria consisted
of ‘diffuse bone marrow fibrosis’ and ‘absence of Philadelphia
chromosome or BCR-ABL rearrangement in peripheral blood
cells’. The six optional criteria in the core set consisted of:
splenomegaly of any grade; anisopoikilocytosis with tear-
drop erythrocytes; the presence of circulating immature
myeloid cells; the presence of circulating erythroblasts; the
presence of clusters of megakaryoblasts and anomalous
megakaryocytes in bone marrow sections; myeloid meta-
plasia. The definition of the disease with the highest final
score was as follows: necessary criteria plus any other two
criteria when splenomegaly is present or any four when
splenomegaly is absent. The use of this definition will help to
standardize the conduct and reporting of clinical studies and
should help practitioners in clinical practice.
Keywords: myelofibrosis with myeloid metaplasia, consensus
conference, diagnostic criteria, chronic myeloproliferative
disorders, myelodysplastic syndromes.
The disorder formerly referred to by various names but
which we will, as a result of the present work, call
myelofibrosis with myeloid metaplasia (MMM), belongs to
the clonal proliferations of haemopoiesis categorized among
the spectrum of chronic myeloproliferative disorders (CMD).
The need to unequivocally distinguish individual clinical
entities among CMD led to ad hoc committees which
developed diagnostic criteria, and the literature now reports
parameters designed to identify certain ones such as chronic
myeloid leukaemia (CML) (Bennett et al, 1994), polycythae-
mia vera (PV) (Berlin, 1975) and essential thrombocythae-
mia (ET) (Murphy et al, 1986). Criteria for the diagnosis of
MMM were first proposed by Laszlo (1975) of the Poly-
cythemia Vera Study Group (PVSG). The features agreed
upon included fibrosis involving more than one-third the
sectional area of a bone marrow biopsy, splenomegaly,
leucoerythroblastic blood reaction, the absence of an
increased red blood cell mass and the absence of the
Philadelphia chromosome. However, over the last 20 years
a wide range of clinical and pathologic phenotypes of the
disease (Bentley et al, 1977; Barosi et al, 1983, 1991; Polino
et al, 1986) and mixed or transitional CMD with features
resembling MMM (Krauss, 1966; Pettit et al, 1976) have
been reported. Moreover, among the disorders categorized
under the heading of myelodysplastic syndromes (MDS)
(Bennett et al, 1982; Kouides & Bennet, 1996), the
possibility of true myeloproliferative characteristics as in
chronic myelomonocytic leukaemia (CMMoL) (Fenaux et al,
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1987; Storniolo et al, 1990; Bennett et al, 1994; Greenberg
et al, 1997; Niemeyer et al, 1997), presentation with bone
marrow fibrosis (Pagliuca et al, 1989; Verhoef et al, 1991;
Maschek et al, 1992; Krishnan & Seldon, 1996) and mixed
myelodysplastic and myeloproliferative features (Neuwirtova
et al, 1996) make the distinction between MMM difficult in
some cases. These reasons led most of the published MMM
series to report patient populations which were less strictly
defined than that required by the originally proposed criteria.
In particular, the parameters of normal or decreased red cell
mass (Barosi et al, 1988; Visani et al, 1990; Dupriez et al,
1996), and the presence of splenomegaly at diagnosis of the
disease (Cheng, 1979; Rupoli et al, 1994; Barosi et al, 1998),
do not always seem to have been met in all patients.
Moreover, others did not consider bone marrow fibrosis to be
a necessary diagnostic criterion in early hypercellular stages
when haemopoiesis is characterized by an abnormal
cytologic appearance of megakaryocytes (Georgii et al,
1990; Thiele et al, 1996) and the term ‘chronic megakar-
yocytic-granulocytic myelosis’ was coined to describe the
early nonfibrotic stage of myelofibrosis (Georgii et al, 1990).
The lack of accepted standardization of criteria for
distinguishing among the spectrum of similar forms may
lead to nonhomogenous inclusion of patients in clinical trials
with the risk of reporting bias, ambiguous interpretation of
results, and the inability to compare therapies. Perceiving
the need for rigorous, consistent and feasible criteria for the
diagnosis of MMM, we undertook this project. Our purpose
was to identify a core set of criteria and to develop a
definition of MMM that would aid in the classification of
individual patients as well as be applicable to future clinical
studies. We envisioned that the definition of MMM might also
be useful for physicians assessing patients in routine practice.
METHODS
The Italian Consensus Conference (CC) on Diagnostic
Criteria for MMM Project was developed by a multistep
process, based on the NIH approach (White & Ball, 1985)
with some modifications. This process is described below and
summarized in Fig 1.
An 18-member Advisory Council was formed in June
1995. It was composed of haematologists with experience
and interest in MMM, members of the Italian Cooperative
Group on MMM of the GIMMC (Italian Group on Chronic
Myeloproliferative Diseases), constituted under the auspices
of the Italian Society of Haematology. The objectives of the
Advisory Council were: (1) to define the aims of the project
and to frame the operative and clinical context (needs-
assessment phase); (2) to review the literature for diagnostic
criteria (the literature review phase); (3) to select the
members of the CC Panel and to organize the consensus
development process aimed at defining the disease (the
consensus phase).
The needs-assessment phase. After three successive meetings
and much free discussion, the Advisory Council under the
leadership of the Prime Organizer (G.B.) agreed on the aim of
the project: ‘to choose the best name for and to develop a
diagnostic definition of the disorder that would remain valid
in a set of patients with CMD or MDS’. The Council decided to
use the following terminology throughout the project. A
‘criterion’ refers to a ‘single biological or clinical character-
istic, such as a test result, clinical investigation result, or
histologic characteristic that is assessable and binary
(present/absent)’. A ‘positive’ criterion was defined as a
criterion the presence of which indicated MMM and a
‘negative’ criterion as one the presence of which excluded
MMM. ‘Necessary criterion’ was defined a criterion that must
be present and the presence of which must be ascertained in
order for patients to be defined as having MMM.
The literature review phase. The aims set by the Advisory
Council in reviewing the literature were the following: (1) to
enumerate the criteria used for diagnosing MMM in the
literature (historic criteria); (2) to identify other features of
MMM that could be proposed as diagnostic criteria (newly
proposed criteria); (3) to calculate the sensitivity and
specificity of both historic and newly proposed criteria
(candidate criteria) for MMM among other CMD and MDS.
The Advisory Council searched the MEDLINE database for
relevant articles according to a strategy that included 10
pertinent keywords. Studies published between 1960 and
1996 inclusive were screened and the bibliographies of
retrieved articles and conference proceedings were examined
manually.
For the ‘historic criteria’ search phase, all studies retrieved
were included and the investigators from the Advisory
Council independently gathered the criteria used for the
diagnosis of MMM. Most of the time these were taken from
the Materials and Methods section of the papers, but when
reviews or commentaries were examined the criteria were
drawn from every part of the paper.
Fig 1. Process of choosing the preferred name, the core set of
diagnostic criteria and, using the core set, a definition of MMM.
For the ‘newly proposed criteria’ search phase, only
original papers were retrieved and the members of the
Council were independently assigned to peruse literature
dealing with one of the following topics: clinics, pathology,
cytogenetics, immunology, imaging and isotopic studies and
in vitro cultures. The reviewers were to search for new
candidate criteria for the diagnosis of MMM.
For the calculation of the specificity and sensitivity phase,
only studies dealing with Philadelphia-negative CMD or MDS
with bone marrow fibrosis (the diagnostic context) in which
more than 10 subjects were enrolled and in which data
necessary to calculate both the sensitivity and specificity
were reported were included. The Advisory Council assumed
that the diagnostic characteristic of any criterion drawn
from the literature represented an index of diagnostic
confidence which the scientific community had given to
that criterion. The performance of any criterion was
characterized by its sensitivity and specificity and by its
diagnostic efficiency (true positive plus true negative rates),
i.e. the probability that a criterion correctly identified MMM
patients within the diagnostic context. Diagnostic efficiency
was obtained after correction for disease prevalence, derived
from the incidence and mean duration as reported in the
literature (Bilgrami & Greenberg, 1995; Tefferi et al, 1995a,
b; Maynadie et al, 1996). The Advisory Council assumed that
the disutility or cost of false-positive criteria and the disutility
of false-negative criteria were equal.
The consensus phase. Twelve Italian scientists were asked to
join the Panel for the CC Project. The Panel was composed of
experts in clinical medicine, clinical research, pathology,
outcomes/health services research and medical decision
making. The clinical experts were from the fields of
haematology and medical oncology, and both academic
and hospital representatives were included; they were
chosen for their representativeness and prominent position
in Italian medical societies.
A pre-consensus conference questionnaire was mailed to
each Panel member asking them: (1) to rank the top choice
among the disease designations used by the medical
literature; (2) to select the necessary criteria, that is the
criteria from the list of candidate criteria which should
necessarily be ascertained and be present to diagnose MMM;
(3) to rank the top six choices among candidate criteria,
excluding the necessary ones (optional criteria). An ‘other’
category was provided to add names and criteria not
included in the list. The panelists were also provided with a
booklet that summarized the aims of the Project and the
results of the literature search phase. For all candidate
criteria the statistical performance, when available, was
included. All the questionnaires were returned and the
names of the disease, the necessary criteria and the
candidate criteria were ranked according to their priority
votes. The two necessary and the six optional criteria which
ranked highest formed the core set of criteria.
A CC was held in Bologna, Italy, in May 1997. The
meeting was attended by the 12 members of the CC Panel
with the assistance of two members of the Advisory Council
(G.B. and N.L.L.). The overall aim of the meeting was to
decide upon the final name of the disease and a definition of
the disease based on a core set of criteria, using a
combination of statistical and consensus formation techni-
ques (Delbecq et al, 1975). In order to achieve this there were
three objectives, which are described in consecutive order
below.
1. Rate the two names of the disease receiving the highest
scores from the questionnaire using the nominal group technique.
Participants were asked to silently choose the preferred
name. If an 80% consensus on the preferred name was not
achieved, the choices were discussed in round-robin fashion
and a second vote taken. If an 80% consensus was still not
attained, the name was declared undecidable and no further
attempt was made.
2. Rate each of 46 paper patient profiles as appropriate or not
appropriate for a diagnosis of MMM using the nominal group
technique. Existing data bases were exploited to build 46
patient profiles to be presented to conference attendees. The
GIMMC had conducted a retrospective trial to evaluate the
incidence of blast transformation in MMM (n ¼ 560) (Barosi
et al, 1998) and the Institute of Internal Medicine and
Medical Oncology of the University Hospital of Pavia had
conducted a retrospective trial to evaluate prognostic factors
for MDS (n ¼ 148) (Ascari et al, 1997). These data bases were
selected as a source of patients. The profiles selected were
those of patients with doubts regarding the diagnostic
classification raised by their clinical records. Absolute
values at diagnosis were shown for each criterion. Partici-
pants at the CC were asked to silently rate each of the 46
patient profiles as MMM or not. The moderator then asked
each member how he had voted on each profile. If an 80%
consensus about whether a patient had MMM was not
achieved, the case was discussed in round-robin fashion and
a second vote taken. If an 80% consensus was still not
attained, the patient profile was declared uninterpretable
and was not considered further in the nominal group.
3. Using the physicians’ consensus judgement as the gold
standard, calculate the percent false-positive and false-negative
rates, chi-square, sensitivity and specificity for each of the 90
definitions of MMM. By using combinations of the variables
in the core set selected on the questionnaire, the Advisory
Council developed for testing a set of 90 sound definitions of
MMM. Then the ability of the 90 candidate definitions of the
disease to classify individual patients as having MMM or not
was evaluated, and the agreement between the decision
based on the criteria and the consensus of the physicians was
assessed. Only patient profiles for which physician consensus
was achieved were used. For each definition, we calculated
the chi-square (1 degree of freedom) and the corresponding
P value, sensitivity (ability of the definition to identify as
having MMM a patient who had been classified as having
MMM by the physicians), specificity (ability of the definition
to identify as not having MMM a patient who had been
classified as not having MMM by the physicians), rate of
false-positivity ([number falsely identified as having MMM by
criteria/all patients identified as having MMM] · 100), and
rate of false-negativity ([number falsely identified as not
having MMM by the criteria/all patients identified as not
having MMM] · 100). Two-sided 95% confidence intervals
(one-sided 97·5% for values of 100%) for both sensitivity and
q 1999 Blackwell Science Ltd, British Journal of Haematology 104: 730–737
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specificity were calculated by the exact binomial method.
Those definitions of the disease showing either a sensitivity
or specificity of <80% were eliminated from further
consideration. We used the kappa statistic as an additional
measure of agreement between the physicians’ evaluation
and the definitions: k values > 0·7 were considered to be
evidence of agreement.
RESULTS
Preferred name of the disease
Among the 12 names for the disease found in the literature,
the questionnaires returned showed a preference for:
‘myelofibrosis with myeloid metaplasia’ and ‘idiopathic
myelofibrosis’. Using the consensus formation technique,
the CC Panel agreed upon the designation ‘myelofibrosis
with myeloid metaplasia’.
Candidate criteria to be evaluated
The Advisory Council listed 21 historic criteria (16 positive
and five negative), along with six new positive and 10 new
negative criteria used for the diagnosis of other CMD or MDS,
to be included as candidate criteria for the diagnosis of
MMM. Of this set of 37 criteria, 21 possessed data from the
literature for characterizing their diagnostic performance
within the group of Philadelphia-negative CMD and 14 for
assessing performance within the MDS with bone marrow
fibrosis. Table I reports the sensitivity and specificity of these
criteria and their diagnostic efficiency. These data were
presented to the CC Panel in the booklet for their personal
evaluation.
The four criteria with the highest preference rate from the
questionnaire as necessary for diagnosis were: (1) bone
marrow fibrosis of any grade; (2) bone marrow fibrosis
greater than a third of the biopsy area; (3) absence of the
Philadelphia chromosome in peripheral blood cells; (4) lack
of BCR-ABL rearrangement in peripheral blood cells. When
the other criteria were ranked according to their priority
score, the six criteria for the core set included the following:
(1) splenomegaly of any grade; (2) anisopoikilocytosis with
tear-drop erythrocytes; (3) presence of circulating immature
myeloid cells; (4) presence of circulating erythroblasts; (5)
presence of clusters of megakaryoblasts and anomalous
megakaryocytes in bone marrow sections; (6) myeloid
metaplasia.
Necessary criteria
Using the nominal group technique a consensus was sought
on the necessary criteria chosen by the questionnaire. A
consensus was reached on either presence of the Phila-
delphia chromosome or BCR-ABL rearrangement in periph-
eral blood cells. No consensus on which of the two mutually
exclusive criteria for defining the necessary degree of bone
marrow fibrosis was reached, and the CC Panel suggested
changing the definition of the criterion. After the CC, the
Advisory Council considered the issues raised during the CC
Table I. Diagnostic performance of the criteria for MMM with respect to other Philadelphia-chromosome-negative chronic myeloproliferative
disorders (polycythaemia vera, PV, and essential thrombocythaemia, ET) and myelodysplastic syndromes with bone marrow fibrosis (MDS with
fibrosis). When no data on MDS with bone marrow fibrosis were present in the literature, the diagnostic efficiency was that of PV plus ET alone.
Specificity
MDS with Diagnostic
Criteria Sensitivity PV þ ET fibrosis efficiency
Anisopoikilocytosis with tear-drop erythrocytes 0·90 0·90 0·47 0·89
Anaemia 0·72 0·91 0·05 0·88
Erythroblasts in peripheral blood 0·69 0·95 0·58 0·83
Immature myeloid cells in peripheral blood 0·87 0·85 0·58 0·82
Dry-tap 0·66 0·90 0·15 0·81
Myeloid metaplasia 0·84 0·69 0·69 0·73
Bone marrow fibrosis greater than one third of biopsy area 0·99 0·63 0 0·73
Increase in serum procollagen III peptide 0·75 0·75 – 0·73
Marrow hypocellularity 0·29 0·93 0·77 0·73
Hepatomegaly 0·72 0·67 0·73 0·67
Splenomegaly of any grade 0·92 0·55 0·65 0·61
Spontaneous growth of BFU-E 0·49 0·89 – 0·26
Normal or reduced red cell volume 0·68 0·55 0 0·53
Lymphoadenomegaly 0·11 0·54 0 0·65
Presence of clusters of megakaryoblasts and atypical megakaryocytes 0·60 0·33 – 0·37
Spontaneous growth of CFU-Meg 0·71 0·25 – 0·45
Decrease of marrow fat 0·84 0·12 – 0·31
LAP score normal or increased 0·88 0·08 – 0·31
Absence of Philadelphia chromosome in peripheral blood cells 1 0 0 0·31
Marrow hypercellularity 0·22 0·21 0·35 0·11
q 1999 Blackwell Science Ltd, British Journal of Haematology 104: 730–737
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discussion, reconvened and framed the following alternative
definition of bone marrow fibrosis: ‘microscopic evidence of
reticulin fibres at 100 · in any area of bone marrow sections
in biopsies no smaller than 3 · 15 mm’. The question was
mailed and 80% of the replies agreed with this definition of
the bone marrow fibrosis necessary for diagnosis.
Identification of the best performing definition
The 12 Panel members scored 25 of the 46 patient profiles as
having MMM, eight as not having MMM, and 13 as
uninterpretable. Eight of the 90 definitions of MMM
showed chi-square >10. These eight definitions, their
corresponding chi-square values, sensitivity and specificity,
confidence intervals, P values, false-positive and false-
negative rates are shown in Table II. The definition of
MMM that scored highest was as follows (Table III): diffuse
bone marrow fibrosis necessarily present and Philadelphia
chromosome or BCR-ABL rearrangement in peripheral blood
cells necessarily absent; any two of the other core set criteria
present when splenomegaly is present; any four of the other
core set criteria present when splenomegaly is absent.
DISCUSSION
In this work we report a consensus on the diagnostic
definition of myelofibrosis with myeloid metaplasia. In the
absence of a specific biological marker for the disease, we
were aware that searching for a definition of MMM raised
both a true diagnostic issue, i.e. which diagnostic criteria
and how to use them for the diagnosis, and a classificatory
one, i.e. how to distinguish this disease among a spectrum of
disorders of the same nature and with similar features. To
focus the problem, the Advisory Council clearly stated that
the aim of this project was to arrive at a definition of MMM
within the limited scenario of CMD or MDS.
The task of finding a consensus for diagnostic criteria was
complicated by the fact that the area is usually characterized
by few ad hoc studies reporting the statistical information
needed for summing up the evidence. Actually, of the 37
candidate criteria retrieved from the literature, only 21 had
studies that were useful for evaluating how specific and
sensitive they were in classifying MMM among other chronic
Philadelphia-negative CMD, and only 14 showed such
studies for a similar evaluation among MDS with bone
marrow fibrosis, i.e. our diagnostic context. The Panel put
the highest value on criteria sensitivity when it had to choose
the criteria that must be present for diagnosis, i.e. absence of
the genetic marker of CML and evidence of bone marrow
fibrosis, and put value on the overall measure of diagnostic
efficiency, i.e. a summary index of positive and negative
predictive value, when it had to identify the optional criteria.
Using consensus formation and a statistical approach, the
results of this project suggest that MMM can be defined as
follows (Table III): bone marrow fibrosis and lack of the
genetic marker of CML necessarily present; any two of the six
optional criteria of the core set present if splenomegaly is
present, or any four of the optional core set criteria present if
splenomegaly is absent. As most of the formulations of the
criteria were drawn from the literature, one could note
ambiguity in these formulations. For example, pathologists
might feel uncertain about how to define exactly ‘clusters of
megakaryoblasts and anomalous megakaryocytes in the
bone marrow sections’ (Rupoli et al, 1994; Thiele et al,
1996). ‘Myeloid metaplasia’ is also a criterion for which the
biological meaning is clear but for which the methods of
detection vary. However, investigators in future trials on the
disease should feel free to replace this definition of the
criterion with other more specific definitions or to better
specify which method of assessment should be fulfilled for the
inclusion of patients. The only source of disagreement about
a criterion definition among the consensus panelists was on
bone marrow fibrosis. As a result, the new formulation
presented by the Advisory Committee and accepted by the
panelists is as follows: ‘microscopic evidence of reticulin
fibres at 100· in any area of bone marrow sections in
biopsies no smaller than 3 · 15 mm’.
The definition of MMM formulated in this work is one that
was constructed with features of the disease that are not
universally agreed upon for enrolling cases in clinical trials
or used by clinicians to diagnose the disease in individual
patients. The panelists agreed on the necessary presence of
bone marrow fibrosis for defining MMM. As a consequence,
in CMD without myelofibrosis but with megakaryocyte
maturation defects and atypical histotopography, classified
by some pathologists as stage 0 myelofibrosis (Georgii et al,
1990; Thiele et al, 1996), a diagnosis of MMM should
avoided. The unnecessary red blood cell volume measure-
ment means that both transitional disorders with increased
red cell volume and bone marrow fibrosis (Pettit et al, 1976),
as well as post-polycythaemia myeloid metaplasia with
persistently increased red cell volume (Ellis et al, 1986),
should be not strictly excluded. It is thus the intention of the
panelists that the term MMM encompass patients with both
idiopathic disease and one that transforms from other CMD.
The results of this work derived from a structured
consensus process and a statistical analysis on the experts’
reactions to 42 real cases. The performing characteristics of
Table III. The Italian criteria for the diagnosis of myelofibrosis with
myeloid metaplasia.
Necessary criteria
A. Diffuse bone marrow fibrosis
B. Absence of Philadelphia chromosome or BCR-ABL rearrange-
ment in peripheral blood cells
Optional criteria
1. Splenomegaly of any grade
2. Anisopoikilocytosis with tear-drop erythrocytes
3. Presence of circulating immature myeloid cells
4. Presence of circulating erythroblasts
5. Presence of cluster of megakaryoblasts and anomalous mega-
karyocytes in bone marrow sections
6. Myeloid metaplasia
Diagnosis of MMM is acceptable if the following combinations are
present: the two necessary criteria plus any other two optional
criteria when splenomegaly is present; the two necessary criteria
plus any other four optional criteria when splenomegaly is absent.
the resulting disease definition, i.e. its specificity and
sensitivity, should be interpreted as a result of uncertainty
inherent both to the consensus process and to the panelists’
idea of the disease. The former depends on the numbers
chosen for the sample of experts and cases used during the
consensus process; the latter captures the absence of clear
markers for defining the disease. The resulting definition had
100% specificity and 88% sensitivity, which thus assured no
false positives, but some false negatives. These criteria
therefore seemed to be appropriate when used for enrolling
patients in clinical trials.
A consequence of the results of this Project is that patients
to be included in studies on MMM will have to be analysed for
the absence of the CML genetic marker, even in cases in
which a diagnosis of MMM seems clear. Performing a
chromosomal or molecular study in MMM patients is not
the rule today (Kvasnicka et al, 1997; Visani et al, 1990;
Dupriez et al, 1996). Another important consequence of the
results is that a pivotal role in the diagnosis is in the hands of
pathologists. They have to make a judgment on bone
marrow fibrosis and on the presence of pathological clusters
of megakaryoblasts or anomalous megakaryocytes.
In conclusion, this Project proposes a definition of MMM
that has >80% sensitivity and specificity. Use of the criteria
forming the definition should be required for communication
within the scientific community and for the inclusion of
patients in any scientific trials.
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